Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.95B | 4.99B | 5.06B | 5.20B | 5.80B | 5.54B |
Gross Profit | 3.83B | 3.89B | 3.87B | 4.03B | 4.56B | 4.39B |
EBITDA | 560.40M | 509.10M | 482.20M | 672.70M | 854.60M | 740.90M |
Net Income | 280.40M | 254.30M | 142.20M | 321.30M | 447.20M | 372.60M |
Balance Sheet | ||||||
Total Assets | 2.68B | 2.73B | 2.81B | 2.73B | 2.82B | 3.08B |
Cash, Cash Equivalents and Short-Term Investments | 329.40M | 415.30M | 575.20M | 508.00M | 601.50M | 1.05B |
Total Debt | 2.40B | 2.47B | 2.77B | 2.88B | 2.96B | 2.64B |
Total Liabilities | 3.42B | 3.53B | 3.87B | 4.00B | 4.21B | 3.93B |
Stockholders Equity | -736.00M | -801.10M | -1.06B | -1.27B | -1.39B | -856.10M |
Cash Flow | ||||||
Free Cash Flow | 164.40M | 163.40M | 222.50M | 196.10M | 308.90M | 516.60M |
Operating Cash Flow | 271.80M | 285.40M | 357.50M | 352.50M | 460.30M | 628.60M |
Investing Cash Flow | -70.60M | -84.60M | -134.80M | -156.20M | -156.40M | -123.20M |
Financing Cash Flow | -249.30M | -335.30M | -148.30M | -264.70M | -728.60M | -320.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $2.92B | 20.34 | 8.22% | ― | 14.22% | -1.81% | |
72 Outperform | $918.67M | 2.80 | -31.74% | ― | -2.25% | 288.79% | |
72 Outperform | $283.93M | 21.59 | 9.15% | ― | 4.33% | -6.33% | |
70 Outperform | $535.73M | 16.27 | 6.54% | ― | 2.75% | -37.25% | |
65 Neutral | $1.97B | 15.35 | 8.70% | ― | -4.90% | 0.29% | |
62 Neutral | HK$21.76B | 9.90 | 5.51% | 4.90% | 1.24% | -22.96% | |
61 Neutral | $2.12B | 25.33 | 8.79% | 2.85% | 0.50% | -4.46% |
Herbalife reported its financial results for the second quarter of 2025, with net sales of $1.3 billion, slightly down by 1.7% compared to the previous year, impacted by foreign currency headwinds. The company exceeded its adjusted EBITDA guidance and raised its full-year net sales and adjusted EBITDA outlook. Recent developments include the launch of MultiBurn, a new weight-loss supplement, and the unveiling of the beta version of the Pro2col app, indicating a focus on innovation and expanding product offerings. These initiatives, along with strong distributor engagement programs, are expected to drive future growth and enhance Herbalife’s market position.
The most recent analyst rating on (HLF) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Herbalife stock, see the HLF Stock Forecast page.
On June 10, 2025, Herbalife Ltd. and its subsidiary issued a notice to redeem $50 million of their 7.875% Senior Notes due 2025. The redemption is scheduled for June 30, 2025, at a price of $1,000 per $1,000 principal amount, impacting the company’s financial obligations and potentially its market positioning.
The most recent analyst rating on (HLF) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Herbalife stock, see the HLF Stock Forecast page.